These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 21426072)

  • 21. beta-Secretase, APP and Abeta in Alzheimer's disease.
    Vassar R
    Subcell Biochem; 2005; 38():79-103. PubMed ID: 15709474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. gamma-Secretase as a target for drug intervention in Alzheimer's disease.
    Harrison T; Churcher I; Beher D
    Curr Opin Drug Discov Devel; 2004 Sep; 7(5):709-19. PubMed ID: 15503873
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase.
    Zhu Y; Xiao K; Ma L; Xiong B; Fu Y; Yu H; Wang W; Wang X; Hu D; Peng H; Li J; Gong Q; Chai Q; Tang X; Zhang H; Li J; Shen J
    Bioorg Med Chem; 2009 Feb; 17(4):1600-13. PubMed ID: 19162488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficient four-drug cocktail therapy targeting amyloid-β peptide for Alzheimer's disease.
    Asai M; Iwata N; Tomita T; Iwatsubo T; Ishiura S; Saido TC; Maruyama K
    J Neurosci Res; 2010 Dec; 88(16):3588-97. PubMed ID: 20890992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Secretase inhibitors for Alzheimer's disease: challenges of a promiscuous protease.
    Pollack SJ; Lewis H
    Curr Opin Investig Drugs; 2005 Jan; 6(1):35-47. PubMed ID: 15675602
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Disease modifying strategies for the treatment of Alzheimer's disease targeted at modulating levels of the beta-amyloid peptide.
    Pangalos MN; Jacobsen SJ; Reinhart PH
    Biochem Soc Trans; 2005 Aug; 33(Pt 4):553-8. PubMed ID: 16042543
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Depletion of CXCR2 inhibits γ-secretase activity and amyloid-β production in a murine model of Alzheimer's disease.
    Bakshi P; Margenthaler E; Reed J; Crawford F; Mullan M
    Cytokine; 2011 Feb; 53(2):163-9. PubMed ID: 21084199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A two decade contribution of molecular cell biology to the centennial of Alzheimer's disease: are we progressing toward therapy?
    Dillen K; Annaert W
    Int Rev Cytol; 2006; 254():215-300. PubMed ID: 17148000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure guided P1' modifications of HEA derived β-secretase inhibitors for the treatment of Alzheimer's disease.
    Monenschein H; Horne DB; Bartberger MD; Hitchcock SA; Nguyen TT; Patel VF; Pennington LD; Zhong W
    Bioorg Med Chem Lett; 2012 Jun; 22(11):3607-11. PubMed ID: 22572583
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application.
    Pietrzik C; Behl C
    Int J Exp Pathol; 2005 Jun; 86(3):173-85. PubMed ID: 15910551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changing perspectives on Alzheimer's disease: thinking outside the amyloid box.
    D'Alton S; George DR
    J Alzheimers Dis; 2011; 25(4):571-81. PubMed ID: 21460435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Critical evaluation of current Alzheimer's drug discovery (2018-19) & futuristic Alzheimer drug model approach.
    Dorababu A
    Bioorg Chem; 2019 Dec; 93():103299. PubMed ID: 31586701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New developments in mild cognitive impairment and Alzheimer's disease.
    Schott JM; Kennedy J; Fox NC
    Curr Opin Neurol; 2006 Dec; 19(6):552-8. PubMed ID: 17102693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacotherapeutic targets in Alzheimer's disease.
    Biran Y; Masters CL; Barnham KJ; Bush AI; Adlard PA
    J Cell Mol Med; 2009 Jan; 13(1):61-86. PubMed ID: 19040415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Data-driven modeling of Alzheimer disease pathogenesis.
    Anastasio TJ
    J Theor Biol; 2011 Dec; 290():60-72. PubMed ID: 21920373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular biology of Alzheimer's dementia and its clinical relevance to early diagnosis and new therapeutic strategies.
    Wiltfang J; Esselmann H; Maler JM; Bleich S; Hüther G; Kornhuber J
    Gerontology; 2001; 47(2):65-71. PubMed ID: 11287729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Elucidation of mechanism underlying amyloid-beta peptide aggregation and its neurotoxicity expression and inhibition of these molecular processes by beneficial synthetic and natural compounds with low-molecular weights-new approaches to fundamental treatment and prevention of Alzheimer's disease].
    Yamakuni T
    Yakugaku Zasshi; 2010 Apr; 130(4):493-4. PubMed ID: 20371991
    [No Abstract]   [Full Text] [Related]  

  • 38. Alzheimer's disease: on the verges of treatment and prevention.
    Burns A
    Lancet Neurol; 2009 Jan; 8(1):4-5. PubMed ID: 19081500
    [No Abstract]   [Full Text] [Related]  

  • 39. [Progress of treating Alzheimer's diseases by "A beta cascade hypothesis" based Chinese materia medica].
    Li N
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 Dec; 31(12):1714-20. PubMed ID: 24354049
    [No Abstract]   [Full Text] [Related]  

  • 40. Alzheimer's failure raises questions about disease-modifying strategies.
    Extance A
    Nat Rev Drug Discov; 2010 Oct; 9(10):749-51. PubMed ID: 20885394
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.